Neuromodulation has shown some benefit in treatment of obesity and it is less invasive than the gastric banding and gastric bypass, which are surgical treatment option for obesity. Obesity treating neuromodulation system works by manipulation the appetite signal between gut and the brain.
The global Obesity Treating Neuromodulation System market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North America region dominates the global obesity treating neuromodulation system market and is expected to continue to dominate the market over the forecast period. High adoption of neuromodulation system and increased regulatory approval of these devices in the region is expected to be factor for the growth of obesity treating neuromodulation system market. Europe is the second biggest market for the obesity treating neuromodulation system. Increasing prevalence of obesity and presence of market players is also driving the market of obesity treating neuromodulation system market in North America and Europe.
Report Includes:
This report presents an overview of global market for Obesity Treating Neuromodulation System, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Obesity Treating Neuromodulation System, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Obesity Treating Neuromodulation System, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Obesity Treating Neuromodulation System sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2023. Identification of the major stakeholders in the global Obesity Treating Neuromodulation System market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2029. Evaluation and forecast the market size for Obesity Treating Neuromodulation System sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Medtronic, Cyberonics, Abbott, BioControl Medical, Leptos Medical, ReShape Lifesciences, Nevro and Nuvectra, etc.
By Company
Medtronic
Cyberonics
Abbott
BioControl Medical
Leptos Medical
ReShape Lifesciences
Nevro
Nuvectra
Segment by Type
Vagus Nerve Stimulator
Splanchnic Nerve Stimulator
Deep Brain Stimulator
Spinal Cord Stimulator
Autonomous Nerve Stimulator
Others
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Obesity Treating Neuromodulation System in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Obesity Treating Neuromodulation System manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: China by type, by application sales and revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Obesity Treating Neuromodulation System sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Study Coverage
1.1 Obesity Treating Neuromodulation System Product Introduction
1.2 麻豆原创 by Type
1.2.1 Global Obesity Treating Neuromodulation System 麻豆原创 Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Vagus Nerve Stimulator
1.2.3 Splanchnic Nerve Stimulator
1.2.4 Deep Brain Stimulator
1.2.5 Spinal Cord Stimulator
1.2.6 Autonomous Nerve Stimulator
1.2.7 Others
1.3 麻豆原创 by Application
1.3.1 Global Obesity Treating Neuromodulation System 麻豆原创 Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Obesity Treating Neuromodulation System Sales Estimates and Forecasts 2018-2029
2.2 Global Obesity Treating Neuromodulation System Revenue by Region
2.2.1 Global Obesity Treating Neuromodulation System Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Obesity Treating Neuromodulation System Revenue by Region (2018-2023)
2.2.3 Global Obesity Treating Neuromodulation System Revenue by Region (2024-2029)
2.2.4 Global Obesity Treating Neuromodulation System Revenue 麻豆原创 Share by Region (2018-2029)
2.3 Global Obesity Treating Neuromodulation System Sales Estimates and Forecasts 2018-2029
2.4 Global Obesity Treating Neuromodulation System Sales by Region
2.4.1 Global Obesity Treating Neuromodulation System Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Obesity Treating Neuromodulation System Sales by Region (2018-2023)
2.4.3 Global Obesity Treating Neuromodulation System Sales by Region (2024-2029)
2.4.4 Global Obesity Treating Neuromodulation System Sales 麻豆原创 Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Obesity Treating Neuromodulation System Sales by Manufacturers
3.1.1 Global Obesity Treating Neuromodulation System Sales by Manufacturers (2018-2023)
3.1.2 Global Obesity Treating Neuromodulation System Sales 麻豆原创 Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Obesity Treating Neuromodulation System in 2022
3.2 Global Obesity Treating Neuromodulation System Revenue by Manufacturers
3.2.1 Global Obesity Treating Neuromodulation System Revenue by Manufacturers (2018-2023)
3.2.2 Global Obesity Treating Neuromodulation System Revenue 麻豆原创 Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Obesity Treating Neuromodulation System Revenue in 2022
3.3 Global Key Players of Obesity Treating Neuromodulation System, Industry Ranking, 2021 VS 2022 VS 2023
3.4 Global Obesity Treating Neuromodulation System Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers 麻豆原创 Concentration Ratio (CR5 and HHI)
3.5.2 Global Obesity Treating Neuromodulation System 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Obesity Treating Neuromodulation System, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Obesity Treating Neuromodulation System, Product Offered and Application
3.8 Global Key Manufacturers of Obesity Treating Neuromodulation System, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 麻豆原创 Size by Type
4.1 Global Obesity Treating Neuromodulation System Sales by Type
4.1.1 Global Obesity Treating Neuromodulation System Historical Sales by Type (2018-2023)
4.1.2 Global Obesity Treating Neuromodulation System Forecasted Sales by Type (2024-2029)
4.1.3 Global Obesity Treating Neuromodulation System Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Obesity Treating Neuromodulation System Revenue by Type
4.2.1 Global Obesity Treating Neuromodulation System Historical Revenue by Type (2018-2023)
4.2.2 Global Obesity Treating Neuromodulation System Forecasted Revenue by Type (2024-2029)
4.2.3 Global Obesity Treating Neuromodulation System Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Obesity Treating Neuromodulation System Price by Type
4.3.1 Global Obesity Treating Neuromodulation System Price by Type (2018-2023)
4.3.2 Global Obesity Treating Neuromodulation System Price Forecast by Type (2024-2029)
5 麻豆原创 Size by Application
5.1 Global Obesity Treating Neuromodulation System Sales by Application
5.1.1 Global Obesity Treating Neuromodulation System Historical Sales by Application (2018-2023)
5.1.2 Global Obesity Treating Neuromodulation System Forecasted Sales by Application (2024-2029)
5.1.3 Global Obesity Treating Neuromodulation System Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Obesity Treating Neuromodulation System Revenue by Application
5.2.1 Global Obesity Treating Neuromodulation System Historical Revenue by Application (2018-2023)
5.2.2 Global Obesity Treating Neuromodulation System Forecasted Revenue by Application (2024-2029)
5.2.3 Global Obesity Treating Neuromodulation System Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Obesity Treating Neuromodulation System Price by Application
5.3.1 Global Obesity Treating Neuromodulation System Price by Application (2018-2023)
5.3.2 Global Obesity Treating Neuromodulation System Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Obesity Treating Neuromodulation System 麻豆原创 Size by Type
6.1.1 US & Canada Obesity Treating Neuromodulation System Sales by Type (2018-2029)
6.1.2 US & Canada Obesity Treating Neuromodulation System Revenue by Type (2018-2029)
6.2 US & Canada Obesity Treating Neuromodulation System 麻豆原创 Size by Application
6.2.1 US & Canada Obesity Treating Neuromodulation System Sales by Application (2018-2029)
6.2.2 US & Canada Obesity Treating Neuromodulation System Revenue by Application (2018-2029)
6.3 US & Canada Obesity Treating Neuromodulation System 麻豆原创 Size by Country
6.3.1 US & Canada Obesity Treating Neuromodulation System Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Obesity Treating Neuromodulation System Sales by Country (2018-2029)
6.3.3 US & Canada Obesity Treating Neuromodulation System Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Obesity Treating Neuromodulation System 麻豆原创 Size by Type
7.1.1 Europe Obesity Treating Neuromodulation System Sales by Type (2018-2029)
7.1.2 Europe Obesity Treating Neuromodulation System Revenue by Type (2018-2029)
7.2 Europe Obesity Treating Neuromodulation System 麻豆原创 Size by Application
7.2.1 Europe Obesity Treating Neuromodulation System Sales by Application (2018-2029)
7.2.2 Europe Obesity Treating Neuromodulation System Revenue by Application (2018-2029)
7.3 Europe Obesity Treating Neuromodulation System 麻豆原创 Size by Country
7.3.1 Europe Obesity Treating Neuromodulation System Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Obesity Treating Neuromodulation System Sales by Country (2018-2029)
7.3.3 Europe Obesity Treating Neuromodulation System Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Obesity Treating Neuromodulation System 麻豆原创 Size
8.1.1 China Obesity Treating Neuromodulation System Sales (2018-2029)
8.1.2 China Obesity Treating Neuromodulation System Revenue (2018-2029)
8.2 China Obesity Treating Neuromodulation System 麻豆原创 Size by Application
8.2.1 China Obesity Treating Neuromodulation System Sales by Application (2018-2029)
8.2.2 China Obesity Treating Neuromodulation System Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Obesity Treating Neuromodulation System 麻豆原创 Size by Type
9.1.1 Asia Obesity Treating Neuromodulation System Sales by Type (2018-2029)
9.1.2 Asia Obesity Treating Neuromodulation System Revenue by Type (2018-2029)
9.2 Asia Obesity Treating Neuromodulation System 麻豆原创 Size by Application
9.2.1 Asia Obesity Treating Neuromodulation System Sales by Application (2018-2029)
9.2.2 Asia Obesity Treating Neuromodulation System Revenue by Application (2018-2029)
9.3 Asia Obesity Treating Neuromodulation System Sales by Region
9.3.1 Asia Obesity Treating Neuromodulation System Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Obesity Treating Neuromodulation System Revenue by Region (2018-2029)
9.3.3 Asia Obesity Treating Neuromodulation System Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Obesity Treating Neuromodulation System 麻豆原创 Size by Type
10.1.1 Middle East, Africa and Latin America Obesity Treating Neuromodulation System Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Obesity Treating Neuromodulation System Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Obesity Treating Neuromodulation System 麻豆原创 Size by Application
10.2.1 Middle East, Africa and Latin America Obesity Treating Neuromodulation System Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Obesity Treating Neuromodulation System Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Obesity Treating Neuromodulation System Sales by Country
10.3.1 Middle East, Africa and Latin America Obesity Treating Neuromodulation System Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Obesity Treating Neuromodulation System Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Obesity Treating Neuromodulation System Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Medtronic
11.1.1 Medtronic Company Information
11.1.2 Medtronic Overview
11.1.3 Medtronic Obesity Treating Neuromodulation System Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 Medtronic Obesity Treating Neuromodulation System Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Medtronic Recent Developments
11.2 Cyberonics
11.2.1 Cyberonics Company Information
11.2.2 Cyberonics Overview
11.2.3 Cyberonics Obesity Treating Neuromodulation System Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 Cyberonics Obesity Treating Neuromodulation System Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Cyberonics Recent Developments
11.3 Abbott
11.3.1 Abbott Company Information
11.3.2 Abbott Overview
11.3.3 Abbott Obesity Treating Neuromodulation System Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 Abbott Obesity Treating Neuromodulation System Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Abbott Recent Developments
11.4 BioControl Medical
11.4.1 BioControl Medical Company Information
11.4.2 BioControl Medical Overview
11.4.3 BioControl Medical Obesity Treating Neuromodulation System Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 BioControl Medical Obesity Treating Neuromodulation System Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 BioControl Medical Recent Developments
11.5 Leptos Medical
11.5.1 Leptos Medical Company Information
11.5.2 Leptos Medical Overview
11.5.3 Leptos Medical Obesity Treating Neuromodulation System Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 Leptos Medical Obesity Treating Neuromodulation System Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Leptos Medical Recent Developments
11.6 ReShape Lifesciences
11.6.1 ReShape Lifesciences Company Information
11.6.2 ReShape Lifesciences Overview
11.6.3 ReShape Lifesciences Obesity Treating Neuromodulation System Sales, Price, Revenue and Gross Margin (2018-2023)
11.6.4 ReShape Lifesciences Obesity Treating Neuromodulation System Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 ReShape Lifesciences Recent Developments
11.7 Nevro
11.7.1 Nevro Company Information
11.7.2 Nevro Overview
11.7.3 Nevro Obesity Treating Neuromodulation System Sales, Price, Revenue and Gross Margin (2018-2023)
11.7.4 Nevro Obesity Treating Neuromodulation System Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Nevro Recent Developments
11.8 Nuvectra
11.8.1 Nuvectra Company Information
11.8.2 Nuvectra Overview
11.8.3 Nuvectra Obesity Treating Neuromodulation System Sales, Price, Revenue and Gross Margin (2018-2023)
11.8.4 Nuvectra Obesity Treating Neuromodulation System Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Nuvectra Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Obesity Treating Neuromodulation System Industry Chain Analysis
12.2 Obesity Treating Neuromodulation System Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Obesity Treating Neuromodulation System Production Mode & Process
12.4 Obesity Treating Neuromodulation System Sales and 麻豆原创ing
12.4.1 Obesity Treating Neuromodulation System Sales Channels
12.4.2 Obesity Treating Neuromodulation System Distributors
12.5 Obesity Treating Neuromodulation System Customers
13 麻豆原创 Dynamics
13.1 Obesity Treating Neuromodulation System Industry Trends
13.2 Obesity Treating Neuromodulation System 麻豆原创 Drivers
13.3 Obesity Treating Neuromodulation System 麻豆原创 Challenges
13.4 Obesity Treating Neuromodulation System 麻豆原创 Restraints
14 Key Findings in The Global Obesity Treating Neuromodulation System Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Medtronic
Cyberonics
Abbott
BioControl Medical
Leptos Medical
ReShape Lifesciences
Nevro
Nuvectra
听
听
*If Applicable.
